Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment

ABSTRACT: Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment

PROVIDER: PRJNA601726 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11587615.fastq.gz	Fastqsanger.gz
	SRR11587616.fastq.gz	Fastqsanger.gz
	SRR11587617.fastq.gz	Fastqsanger.gz
	SRR11587618.fastq.gz	Fastqsanger.gz
	SRR11587619.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 292

Similar Datasets

Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.

Project description:Bone metastases are devastating complications of cancer. They are particularly common in prostate cancer (PCa), represent incurable disease, and are refractory to immunotherapy. We seek to define distinct features of the bone marrow (BM) microenvironment by analyzing single cells from bone metastatic prostate tumors, involved BM, uninvolved BM, and BM from cancer-free, orthopedic patients, and healthy individuals. Metastatic PCa is associated with multifaceted immune distortion, specifically exhaustion of distinct T cell subsets, appearance of macrophages with states specific to PCa bone metastases. The chemokine CCL20 is notably overexpressed by myeloid cells, as is its cognate CCR6 receptor on T cells. Disruption of the CCL20-CCR6 axis in mice with syngeneic PCa bone metastases restores T cell reactivity and significantly prolongs animal survival. Comparative high-resolution analysis of PCa bone metastases shows a targeted approach for relieving local immunosuppression for therapeutic effect.

| S-EPMC8578470 | biostudies-literature

Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment

Project description:We collected unique sets of tissue fractions from each patient: solid metastatic tissue (Tumor fraction), liquid bone marrow at the site of the metastasis (Involved), as well as liquid bone marrow from a vertebral body distant from the tumor site (Distal). This allowed for a comparison within the same individual, controlling for inter-individual variation. Bone marrow samples from patients undergoing hip replacement surgery (Benign) served as a non-malignant comparator group. The transcriptional composition of all samples was assessed using single-cell RNA-seq (scRNA-seq).

2021-08-29 | GSE143791 | GEO

Immunosuppressive microenvironment restrains chemotherapy efficacy in liver metastases of triple-negative breast cancer

Project description:This study investigates the role of the immune microenvironment in the efficacy of chemotherapy for triple-negative breast cancer (TNBC) liver metastases compared to primary tumors. Using mouse models, we assessed chemotherapeutic efficacy and characterized intratumoral T lymphocytes and macrophages via RNA sequencing, immunohistochemistry, and flow cytometry. We found that liver metastases had a less effective response to chemotherapy compared to subcutaneous tumors, linked to reduced CD8+ T cell infiltration and macrophage activation. Chemotherapy induced an immunosuppressive shift, with neutrophil extracellular traps (NETs) accumulating in liver metastases and macrophages and T cells showing impaired functionality in the primary tumors. Combining macrophage activators or NETs inhibitors with chemotherapy improved outcomes. Our findings highlight the importance of tumor site-specific immune microenvironmental differences in chemotherapy responses and suggest that targeted therapies could enhance chemotherapy efficacy.

2025-06-25 | GSE276098 | GEO

Immunosuppressive microenvironment restrains chemotherapy efficacy in liver metastases of triple-negative breast cancer

Project description:Immunosuppressive microenvironment restrains chemotherapy efficacy in liver metastases of triple-negative breast cancer

| PRJNA1154683 | ENA

Immunosuppressive tumor microenvironment of osteosarcoma [Spatial transcriptomics]

Project description:Immunosuppressive tumor microenvironment of osteosarcoma [Spatial transcriptomics]

| PRJNA1272124 | ENA

Immunosuppressive tumor microenvironment of osteosarcoma [scRNA-seq]

Project description:Immunosuppressive tumor microenvironment of osteosarcoma [scRNA-seq]

| PRJNA1272125 | ENA

Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases

Project description:Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases

| PRJNA779738 | ENA

Targeting TNK2 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer

Project description:In this study, we utilized spatial transcriptome analysis, genomic copy number variation mutation profiling, and single-cell sequencing to identify an abnormal overexpression of TNK2, which is inversely correlated with PDAC prognosis and the development of an immune-suppressive microenvironment. Previous research has hinted at TNK2's role in tumor progression and its correlation with patient survival in various cancers, yet its involvement in the PDAC immune microenvironment and resistance to immunotherapy remains unexplored. Our findings reveal that TNK2 overexpression influences the formation of an immunosuppressive microenvironment, as demonstrated by cell communication analysis and immune landscape profiling. Additionally, TNK2 phosphorylates and activates STAT5a at the Y694 site, resulting in the upregulation of immune checkpoint HVEM and the exhaustion of CD8+ T cells. Treatment with AIM100, which disrupts the TNK2-STAT5a-HVEM regulatory axis, markedly mitigates the immunosuppressive microenvironment and enhances sensitivity to PD-1 inhibitors and AG chemotherapy.

2025-10-11 | PXD055503 | Pride

Chil3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases [RNA-Seq]

Project description:Bone metastases remain incurable and respond poorly to immune checkpoint blockade (ICB) therapy. The impact of neutrophil maturation in cancer remains largely unknown, especially in refractory tumors including bone metastases. Here, we observed the predominance of immature neutrophils in the bone metastasis microenvironment of both mouse models and cancer patients. DKK1 induces the immature-like functional state in neutrophils, which exert robust immunosuppressive capabilities to inhibit anti-tumor response of CD8+ T cells. Mechanistically, driven by the DKK1-CKAP4-STAT6 signaling, Chil3 expression is identified and required for the immune suppression mediated by immature neutrophils in bone metastases. Moreover, using multiple syngeneic and human immune system (HIS) mouse models, we found that DKK1 blockade efficiently allows neutrophil maturation to improve the immune microenvironment, controls tumor progression, and enhances ICB therapy response in bone metastases. Thus, our findings uncover an essential role for immature neutrophils in cancer, especially in bone metastases, and propose a potential strategy modulating neutrophils to improve cancer immunotherapy.

2025-06-01 | GSE295537 | GEO

Chil3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases [scRNA-seq]

2025-06-01 | GSE295533 | GEO